Fudim, M., Lopes, R., Alexander, J., Wojdyla, D., Ezekowitz, J., Hanna, M., … Hohnloser, S. (2018). THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY. In Journal of the American College of Cardiology (Vol. 71, pp. A295–A295). Elsevier BV. https://doi.org/10.1016/s0735-1097(18)30836-2

Fudim, Marat, Renato Lopes, John Alexander, Daniel Wojdyla, Justin Ezekowitz, Michael Hanna, Dan Atar, et al. “THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY.” In Journal of the American College of Cardiology, 71:A295–A295. Elsevier BV, 2018. https://doi.org/10.1016/s0735-1097(18)30836-2.

Fudim M, Lopes R, Alexander J, Wojdyla D, Ezekowitz J, Hanna M, et al. THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY. In: Journal of the American College of Cardiology. Elsevier BV; 2018. p. A295–A295.

Fudim, Marat, et al. “THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY.” Journal of the American College of Cardiology, vol. 71, no. 11, Elsevier BV, 2018, pp. A295–A295. Crossref, doi:10.1016/s0735-1097(18)30836-2.

Fudim M, Lopes R, Alexander J, Wojdyla D, Ezekowitz J, Hanna M, Atar D, Hijazi Z, Bahit M, Lopez-Sendon J, Wallentin L, Granger C, Hohnloser S. THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY. Journal of the American College of Cardiology. Elsevier BV; 2018. p. A295–A295.